Cite
HARVARD Citation
Danese, S. et al. (n.d.). OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn's Disease: Results from the phase 2 GALAXI 1 study. Journal of Crohn's and colitis. pp. S027-S028. [Online].